

# British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA Study)




**Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.**

Over 30,000 patients registered in the study since 2001.

**NOW ACCEPTING NEW REGISTRATIONS AND FOLLOW-UP DATA ONLINE VIA THE NEW WEB PORTAL!**

To sign up please visit <https://bsrbr.org/database/>

## Eligibility for registration

	Diagnosis of Rheumatoid Arthritis		Aged 16 Years or over	Starting eligible biologic treatment	
--	-----------------------------------	---	-----------------------	--------------------------------------	---

### ANTI-TNF

**HUMIRA**  
(adalimumab originator)\*

**ENBREL**  
(etanercept originator)\*

**REMICADE**  
(infliximab originator)\*

\*patients must be biologic, biosimilar & targeted therapy naive to be eligible

### BIOSIMILARS

<b>HULIO</b> (adalimumab)	<b>ERELZI</b> (etanercept)
<b>AMGEVITA</b> (adalimumab)	<b>BENEPALI</b> (etanercept)
<b>HYRIMOZ</b> (adalimumab)	<b>INFLECTRA</b> (infliximab)
<b>IMRALDI</b> (adalimumab)	<b>REMSIMA</b> (infliximab)
<b>RIXATHON</b> (rituximab)	<b>FLIXABI</b> (infliximab)
<b>IDACIO</b> (adalimumab)	

### OTHER TARGETED THERAPIES

**OLUMIANT**  
(baracitinib)


**CIMZIA**  
(certolizumab)

**ROACTEMRA**  
(tocilizumab)

**KEVZARA**  
(sarilumab)

**XELJANZ**  
(tofacitinib)

**RINVOQ**  
(upadacitinib)

Registration within 6 months of the therapy start date\* 

\*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

**Please contact the BSRBR-RA team with any questions**

0161 275 1652 / 7390 [biologics.register@manchester.ac.uk](mailto:biologics.register@manchester.ac.uk)